High-stakes asymmetric upside: REGENXBIO’s validated gene-therapy science is colliding with a fragile balance sheet and binary regulatory catalysts.
Overview
REGENXBIO is a clinical-stage gene therapy company built around its NAV AAV platform, internal manufacturing, and high-value pipeline in retinal disease, Duchenne muscular dystrophy, and rare neurodegenerative disorders. The company has strong scientific validation through ZOLGENSMA royalties and major partnerships with AbbVie and Nippon Shinyaku. However, the investment case is highly binary: promising Phase III RGX-202 data and large market opportunities are offset by a severe Q1 revenue miss, declining royalties, safety scrutiny, and a cash runway only into early 2027.